Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

Patent ExpiryAnnamycinPositive

AI Analysis

Summary

Moleculin Biotech secured a Mexican patent protecting its lung-targeted liposomal annamycin formulation through 2040, strengthening its global intellectual property estate for this proprietary cancer therapy.

Outcome Details

Mexican patent secured protecting lung-targeted liposomal annamycin formulation through 2040

Importance:3/10

Sentiment:

0.60

intellectual propertypatentannamycinliposomal formulationlung metastasesMexico

Related Companies

$CBDY $GBCMD

Read the original article

Published by GlobeNewswire Pharma on September 23, 2026 12:25 PM

Read Original